HUMAN MICROBIOMES AND THEIR ROLES IN DYSBIOSIS, COMMON DISEASES AND NOVEL THERAPEUTIC APPROACHES

The human body is the residence of a large number of commensal (non-pathogenic) and pathogenic microbial species that have co-evolved with the human genome, adaptive immune system and diet. With recent advances in DNA-based technologies, we initiated the exploration of bacterial gene functions and t...

Full description

Bibliographic Details
Main Authors: Jose Ernesto Belizario, Mauro eNapolitano
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-10-01
Series:Frontiers in Microbiology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fmicb.2015.01050/full
id doaj-3d3500a96ca84116b3212eb861286ee1
record_format Article
spelling doaj-3d3500a96ca84116b3212eb861286ee12020-11-25T01:58:24ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2015-10-01610.3389/fmicb.2015.01050151578HUMAN MICROBIOMES AND THEIR ROLES IN DYSBIOSIS, COMMON DISEASES AND NOVEL THERAPEUTIC APPROACHESJose Ernesto Belizario0Mauro eNapolitano1University of Sao PauloUniversity of Sao PauloThe human body is the residence of a large number of commensal (non-pathogenic) and pathogenic microbial species that have co-evolved with the human genome, adaptive immune system and diet. With recent advances in DNA-based technologies, we initiated the exploration of bacterial gene functions and their role in human health. The main goal of the human microbiome project is to characterize the abundance, diversity and functionality of the genes present in all microorganisms that permanently live in different sites of the human body. The gut microbiota expresses over 3.3 million bacterial genes, while the human genome expresses only 20 thousand genes. Microbe gene-products exert pivotal functions via the regulation of food digestion and immune system development. Studies are confirming that manipulation of non-pathogenic bacterial strains in the host can stimulate the recovery of the immune response to pathogenic bacteria causing diseases. Different approaches, including the use of nutraceutics (prebiotics and probiotics) as well as phages engineered with CRISPR/cas systems and quorum sensing systems have been developed as new therapies for controlling dysbiosis (alterations in microbial community) and common diseases (e.g. diabetes and obesity). The designing and production of pharmaceuticals based on our own body’s microbiome is an emerging field and is rapidly growing to be fully explored in the near future. This review provides an outlook on recent findings on the human microbiomes, their impact on health and diseases, and on the development of targeted therapies.http://journal.frontiersin.org/Journal/10.3389/fmicb.2015.01050/fullMetagenomicsQuorum SensingSynbioticsmicrobiomephage therapyPharmacomicrobiomics
collection DOAJ
language English
format Article
sources DOAJ
author Jose Ernesto Belizario
Mauro eNapolitano
spellingShingle Jose Ernesto Belizario
Mauro eNapolitano
HUMAN MICROBIOMES AND THEIR ROLES IN DYSBIOSIS, COMMON DISEASES AND NOVEL THERAPEUTIC APPROACHES
Frontiers in Microbiology
Metagenomics
Quorum Sensing
Synbiotics
microbiome
phage therapy
Pharmacomicrobiomics
author_facet Jose Ernesto Belizario
Mauro eNapolitano
author_sort Jose Ernesto Belizario
title HUMAN MICROBIOMES AND THEIR ROLES IN DYSBIOSIS, COMMON DISEASES AND NOVEL THERAPEUTIC APPROACHES
title_short HUMAN MICROBIOMES AND THEIR ROLES IN DYSBIOSIS, COMMON DISEASES AND NOVEL THERAPEUTIC APPROACHES
title_full HUMAN MICROBIOMES AND THEIR ROLES IN DYSBIOSIS, COMMON DISEASES AND NOVEL THERAPEUTIC APPROACHES
title_fullStr HUMAN MICROBIOMES AND THEIR ROLES IN DYSBIOSIS, COMMON DISEASES AND NOVEL THERAPEUTIC APPROACHES
title_full_unstemmed HUMAN MICROBIOMES AND THEIR ROLES IN DYSBIOSIS, COMMON DISEASES AND NOVEL THERAPEUTIC APPROACHES
title_sort human microbiomes and their roles in dysbiosis, common diseases and novel therapeutic approaches
publisher Frontiers Media S.A.
series Frontiers in Microbiology
issn 1664-302X
publishDate 2015-10-01
description The human body is the residence of a large number of commensal (non-pathogenic) and pathogenic microbial species that have co-evolved with the human genome, adaptive immune system and diet. With recent advances in DNA-based technologies, we initiated the exploration of bacterial gene functions and their role in human health. The main goal of the human microbiome project is to characterize the abundance, diversity and functionality of the genes present in all microorganisms that permanently live in different sites of the human body. The gut microbiota expresses over 3.3 million bacterial genes, while the human genome expresses only 20 thousand genes. Microbe gene-products exert pivotal functions via the regulation of food digestion and immune system development. Studies are confirming that manipulation of non-pathogenic bacterial strains in the host can stimulate the recovery of the immune response to pathogenic bacteria causing diseases. Different approaches, including the use of nutraceutics (prebiotics and probiotics) as well as phages engineered with CRISPR/cas systems and quorum sensing systems have been developed as new therapies for controlling dysbiosis (alterations in microbial community) and common diseases (e.g. diabetes and obesity). The designing and production of pharmaceuticals based on our own body’s microbiome is an emerging field and is rapidly growing to be fully explored in the near future. This review provides an outlook on recent findings on the human microbiomes, their impact on health and diseases, and on the development of targeted therapies.
topic Metagenomics
Quorum Sensing
Synbiotics
microbiome
phage therapy
Pharmacomicrobiomics
url http://journal.frontiersin.org/Journal/10.3389/fmicb.2015.01050/full
work_keys_str_mv AT joseernestobelizario humanmicrobiomesandtheirrolesindysbiosiscommondiseasesandnoveltherapeuticapproaches
AT mauroenapolitano humanmicrobiomesandtheirrolesindysbiosiscommondiseasesandnoveltherapeuticapproaches
_version_ 1724969910180773888